{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:30:31Z","timestamp":1780324231146,"version":"3.54.1"},"reference-count":26,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,1,3]]},"DOI":"10.18632\/oncotarget.13597","type":"journal-article","created":{"date-parts":[[2016,11,25]],"date-time":"2016-11-25T12:11:41Z","timestamp":1480075901000},"page":"1204-1212","source":"Crossref","is-referenced-by-count":7,"title":["Meta-analysis on the association of <i>VEGFR1<\/i> genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients"],"prefix":"10.18632","volume":"8","author":[{"given":"Xiaoyan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epie","family":"Boven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[{"name":"Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Rodr\u00edguez-Antona","sequence":"additional","affiliation":[{"name":"Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"},{"name":"ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Garc\u00eda-Donas","sequence":"additional","affiliation":[{"name":"Spanish Oncology Genitourinary Group (SOGUG), Madrid, Spain"},{"name":"Oncology Unit, Clara Campal Comprehensive Cancer Center, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[{"name":"Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute (CCF), Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Jemal","year":"2015","journal-title":"Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/00000478-200305000-00005","article-title":"Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma","volume":"27","author":"Blute","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","article-title":"Novel approaches in the therapy of metastatic renal cell carcinoma","volume":"23","author":"Figlin","year":"2005","journal-title":"World J Urol"},{"key":"4","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","article-title":"NCCN clinical practice guidelines in oncology: kidney cancer","volume":"7","author":"Kessinger","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"5","first-page":"1","article-title":"Surveillance strategies for renal cell carcinoma patients following nephrectomy","volume":"8","author":"Belldegrun","year":"2006","journal-title":"Rev Urol"},{"key":"6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1464-410X.2004.04605.x","article-title":"Expression of vascular endothelial growth factor protein in human renal cell carcinoma","volume":"93","author":"Ljungberg","year":"2004","journal-title":"BJU Int"},{"key":"7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Baum","year":"2007","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1200\/JCO.2008.21.7679","article-title":"Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity","volume":"27","author":"Gelderblom","year":"2009","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1158\/1078-0432.CCR-10-1828","article-title":"Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib","volume":"17","author":"Wessels","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/S1470-2045(11)70266-2","article-title":"Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study","volume":"12","author":"Moreno","year":"2011","journal-title":"Lancet Oncol"},{"key":"11","first-page":"503","article-title":"Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension","volume":"92","author":"Boven","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"12","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1002\/cncr.26491","article-title":"Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib","volume":"118","author":"Ganapathi","year":"2012","journal-title":"Cancer"},{"key":"13","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/bjc.2012.501","article-title":"VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib","volume":"108","author":"Montironi","year":"2013","journal-title":"Br J Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00280-014-2539-0","article-title":"Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma","volume":"74","author":"Williams","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/bjc.2012.548","article-title":"Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib","volume":"108","author":"de la Taille","year":"2013","journal-title":"Br J Cancer"},{"key":"16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/0284186X.2013.770600","article-title":"VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis","volume":"53","author":"Lerut","year":"2014","journal-title":"Acta Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00432-016-2137-0","article-title":"Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients","volume":"142","author":"Wirth","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13585","article-title":"Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib","author":"Patard","year":"2016","journal-title":"BJU Int"},{"key":"19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/JTO.0000000000000549","article-title":"Functional FLT1 genetic variation is a prognostic factor for recurrence in stage I-III non-small cell lung cancer","volume":"10","author":"Hirsch","year":"2015","journal-title":"J Thorac Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/447655a","article-title":"Replicating genotype-phenotype associations","volume":"447","author":"Daly","year":"2007","journal-title":"Nature"},{"key":"21","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","article-title":"Why most published research findings are false","volume":"2","author":"Ioannidis","year":"2005","journal-title":"PLoS Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"e4037","DOI":"10.1371\/journal.pone.0004037","article-title":"Is replication the gold standard for validating genome-wide association findings?","volume":"3","author":"Deng","year":"2008","journal-title":"PLoS One"},{"key":"23","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/bib\/bbq074","article-title":"Validation in genetic association studies","volume":"12","author":"Konig","year":"2011","journal-title":"Brief Bioinform"},{"key":"24","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00228-015-1935-7","article-title":"Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma","volume":"71","author":"Guchelaar","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"25","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Chi","year":"2009","journal-title":"J Clin Oncol"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Borenstein, Hedges, Higgins, Rothstein. Introduction to meta-analysis. 2009.","DOI":"10.1002\/9780470743386"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T13:31:13Z","timestamp":1589117473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,3]]}},"alternative-id":["13597","27901483"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13597","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]}}}